Immutep Publishes EFTISARC-NEO Presentation Showing No Significant Quality-of-Life Deterioration During Treatment

By Public Technologies
  • Immutep published a medical research presentation on quality-of-life results from its phase II EFTISARC-NEO trial in resectable soft tissue sarcoma.
  • The 40-patient trial found no significant quality-of-life deterioration during preoperative treatment with eftilagimod alfa, pembrolizumab and radiotherapy.
  • Role functioning improved 12.7 points following treatment; social functioning rose 8.1 points, both statistically significant.
  • Fatigue decreased significantly by up to 14.2 points during therapy (p = 0.001).
  • The quality-of-life summary score improved 6.0 points following treatment (p = 0.008), while general health status remained stable.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on October 23, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.